Generic Biologics Approval Process Is Focus Of Employers' Coalition
This article was originally published in The Pink Sheet Daily
Executive Summary
Coalition formed in 2003 to push Medicare Rx bill is preparing for a legislative effort next year on generic biologics. Group also wants $75 mil. budgeted for AHRQ drug comparison research.
You may also be interested in...
FDA Mission Should Not Include Rx Cost Effectiveness, Rep. Allen Says
Comparative studies should be "untainted" by industry's influence, the Maine Democrat says. He urges full appropriation of funding to AHRQ under the new Medicare law.
FDA Pushing Generic Biologics Timetable In Election Year; "Structure" Expected Soon
Acting Commissioner Crawford's remarks on the feasibility of generic biologics reflect FDA's growing confidence that it can develop an approval pathway, after years of considering the issue too complex. He will testify on the issue during a Senate subcommittee hearing April 1.
AHRQ Comparative Effectiveness Research Supported By GOP; Too Late For Budget Request
AHRQ budget request includes just $12 mil. for comparative effectiveness research. Majority Leader Frist, White House say they plan to work on $50 mil. appropriated in Medicare law.